Market Place
Sourcing Support
All News #Library
Biotech
Lipocine Reports Topline Results for LPCN 1154 in PPD Patients
02 Apr 2026 //
PR NEWSWIRE
Lipocine Reveals Full-Year 2025 Financial Results
10 Mar 2026 //
PR NEWSWIRE
Lipocine Completes LPCN 1154 Phase 3 Trial Enrollment
20 Jan 2026 //
PR NEWSWIRE
Lipocine Advances LPCN 1154 In Postpartum Depression Ph3 Trial
12 Jan 2026 //
PR NEWSWIRE
Lipocine`s LPCN 1154 Phase 3 Study Reaches 80% Enrollment
16 Dec 2025 //
PR NEWSWIRE
Lipocine Showcases LPCN 1154 Phase 3 Trial Safety In Postpartum
18 Nov 2025 //
PR NEWSWIRE
Lipocine Reports Q3 2025 Financial Results
06 Nov 2025 //
PR NEWSWIRE
Lipocine Announces 1st Patient Dosed in Ph 3 Trial for LPCN 1154
26 Jun 2025 //
PR NEWSWIRE
Lipocine to Present at A.G.P.`s Healthcare Company Showcase
14 May 2025 //
PR NEWSWIRE
Lipocine Announces Q1 2025 Financial Results
08 May 2025 //
PR NEWSWIRE
Lipocine Announces 2024 Full Year Financial Results
13 Mar 2025 //
PR NEWSWIRE
Lipocine Publishes LPCN 1148 Data at The Liver Meeting 2024
18 Nov 2024 //
PR NEWSWIRE
Lipocine Presents LPCN 1148 Phase 2 Data At EASL Congress 2024
08 May 2024 //
PR NEWSWIRE
Lipocine to Present at Biotech Showcase 2024
19 Dec 2023 //
PR NEWSWIRE
LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis
27 Jul 2023 //
PR NEWSWIRE
Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023
07 Jun 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.